Related Experiment Videos
Propentofylline for dementia
M Frampton1, R J Harvey, V Kirchner
14 Edwin Terrace, Mellifont Avenue, Dun Laoire, Co. Dublin, Ireland. maria.frampton@virgin.net
The Cochrane Database of Systematic Reviews
|June 14, 2003
Summary
Propentofylline shows potential benefits for dementia patients, improving cognition, daily living, and global function. However, limited data and unpublished studies hinder a complete efficacy assessment.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Propentofylline is a novel agent for dementia, crossing the blood-brain barrier.
- It inhibits adenosine uptake and phosphodiesterase, reducing free radicals and microglial activation.
- Its mechanism suggests a disease-modifying potential beyond symptomatic treatment for inflammatory processes in dementia.
Purpose of the Study:
- To determine the clinical efficacy and safety of propentofylline in individuals with dementia.
- To evaluate propentofylline's impact on cognitive function, disease severity, and daily living activities.
Main Methods:
- Systematic review of unconfounded double-blind randomized controlled trials.
- Searched the Cochrane Dementia and Cognitive Improvement Group register.
- Included trials compared propentofylline against placebo or other treatments.
Main Results:
- Propentofylline demonstrated statistically significant improvements in cognition (MMSE) at 12 months.
- Improvements were noted in dementia severity (CGI) and Activities of Daily Living (NAB) at various time points.
- Global assessment (CGI) showed significant benefits at 3 months, but not later; dropouts favored placebo.
Conclusions:
- Limited evidence suggests propentofylline may benefit cognition, global function, and daily living in Alzheimer's and vascular dementia.
- The review's scope was significantly limited by unpublished data from 1200 patients and the manufacturer's non-cooperation.
- Further comprehensive studies are needed to fully ascertain propentofylline's efficacy and safety profile.